News - Unibest Industrial Co., Ltd.

Blogs

Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Cardiovascular Benefits of Semaglutide - Clinical Trial Interpretation
2024-07-23

A recent study published in the international journal Diabetes Care, titled "Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT," has revealed a new benefit of Semaglutide - the cardiovascular benefits. Read More
Semagcare - Semaglutide Tablets Distributor & FDF Development
2024-07-15

Unibest proudly partners with a renowned supplier to bring you Semagcare, a premium product line featuring in-housed developed Semaglutide API and Semaglutide tablets available in 3mg, 7mg, and 14mg dosages.Key FeaturesSemagcare: High-quality Semaglutide tablets intended for diabetes and obesity tre Read More
Drug Briefing: Lenacapavir
2024-06-24

Query Drug：LenacapavirQuery Time：2024-06-24 11:06:36*** Disclaimer *** The information provided here is sourced from resources such as Drugs.com, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Unibest Read More
Groundbreaking HIV Prevention Drug Shows 100% Efficacy in Phase 3 Trial
2024-06-24

A recent Phase 3 clinical trial (NCT04994509), dubbed "PURPOSE 1," has yielded promising results for a new HIV prevention drug, potentially revolutionizing the field of HIV prophylaxis. The study, conducted by Gilead Sciences, evaluated the safety and efficacy of Lenacapavir, a novel long-acting HIV Read More
Market Expansion: Dapagliflozin Receives FDA Approval for Treating Type 2 Diabetes in Children
2024-06-13

AstraZeneca has announced on June 12, 2024, that Farxiga (dapagliflozin) has been approved by the U.S. Food and Drug Administration (FDA) for improving glycemic control in children aged 10 years and above with type 2 diabetes (T2D). The FDA approval is based on the positive results from the Phase 3 Read More
The Complement System: A Frontier in Drug Development
2024-06-12

The complement system has long been recognized as a crucial component of the innate immune system, acting as the first line of defense against invading pathogens. However, recent advancements in understanding this intricate network have unveiled its multifaceted roles in various physiological proces Read More
Avacopan - Orphan Drug with a Growing Market
2024-06-07

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA-associated vasculitis) is a rare but serious autoimmune disease affecting small blood vessels. With a global prevalence estimated between 30-218 cases per million, it leads to inflammation of blood vessels and potential organ damage. C Read More
Tirzepatide Approved by NMPA for Type II Diabetes
2024-05-21

On May 21st, the Chinese National Medical Products Administration (NMPA) approved Tirzepatide (brand name Mounjaro), a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Lilly, for the improvement of glycemic control in adults wi Read More
Opportunities for API Manufacturers in the Expanding Ruxolitinib Market
2024-05-15

Ruxolitinib, a groundbreaking product of Incyte Corp, has demonstrated an impressive evolution in the pharmaceutical market. Its strategic journey from a niche treatment for rare diseases to a versatile solution for more common dermatological conditions not only emphasizes the strategic significance Read More